Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
July 09 2021 - 7:30AM
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a
dermatology therapeutics company developing medications for skin
diseases requiring medical interventions, today announced the
appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler
is a strategic and operational finance leader with over 20 years of
commercial business experience, most recently at a global
pharmaceutical company with annual revenues over $2 billion. Mr.
Kohler is replacing Brian Davis, who is leaving Verrica to pursue
other opportunities.
“Terry’s extensive commercial finance experience across the
pharmaceutical product development landscape, including buy and
bill business model, as well as his commercial acumen across all
classes of trade, will support our commercial preparations for the
potential launch of VP-102 this fall,” said Ted White, Verrica’s
President and Chief Executive Officer. “We are pleased to welcome
Terry to our team and look forward to leveraging his expertise. On
behalf of the company and the Board, I thank Brian for his
dedicated service to Verrica and wish him well.”
“I am thrilled to join Verrica and oversee commercial financial
strategy to advance Verrica’s medical dermatology product
portfolio,” said Mr. Kohler. “I look forward to working with
Verrica’s Chief Commercial Officer and senior management to bring
Verrica’s proprietary treatments to medical providers and
patients.”
Prior to joining Verrica, Mr. Kohler served as Vice President,
Corporate Development and Treasurer and Vice President, U.S.
Branded and Specialty Pharmaceuticals at Endo International PLC, a
publicly traded global specialty pharmaceutical company focused on
branded, sterile and generic pharmaceuticals with annual revenues
over $2 billion and locations in the United States, Ireland, India
and Canada. Previously, Mr. Kohler served as a senior professional
with a middle market investment banking firm, and also held various
roles at Johnson & Johnson. Mr. Kohler holds a B.A. in
International Business and Management from Dickinson College and an
M.B.A. in Finance & Entrepreneurship from the University of
North Carolina. He is a Certified Management Accountant.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing
medications for skin diseases requiring medical interventions.
Verrica’s late-stage product candidate, VP-102, is in development
to treat molluscum, common warts and external genital warts, three
of the largest unmet needs in medical dermatology. Verrica is also
developing VP-103, its second cantharidin-based product candidate,
for the treatment of plantar warts. The Company has also entered a
worldwide license agreement with Lytix Biopharma AS to develop and
commercialize LTX-315 for dermatologic oncology conditions. For
more information, visit www.verrica.com.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “may,” “plan,” “potential,” “will,” and
similar expressions, and are based on Verrica’s current beliefs and
expectations. These forward-looking statements include expectations
regarding the potential approval and commercial launch of VP-102
for the treatment of molluscum and the clinical development of
VP-102 for additional indications. These statements involve risks
and uncertainties that could cause actual results to differ
materially from those reflected in such statements. Risks and
uncertainties that may cause actual results to differ materially
include uncertainties inherent in the drug development process and
the regulatory approval process, Verrica’s reliance on third
parties over which it may not always have full control, and other
risks and uncertainties that are described in Verrica’s Annual
Report on Form 10-K for the year ended December 31, 2020, filed
with the U.S. Securities and Exchange Commission on March 17, 2021,
and other filings Verrica makes with the U.S. Securities and
Exchange Commission. Any forward-looking statements speak only as
of the date of this press release and are based on information
available to Verrica as of the date of this release, and Verrica
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
FOR MORE INFORMATION, PLEASE
CONTACT:Investors:
William WindhamSolebury
Trout646.378.2946wwindham@soleburytrout.com
Media:
Zara LockshinSolebury
Trout646.378.2960zlockshin@soleburytrout.com
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Apr 2024 to May 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From May 2023 to May 2024